For the relief of mild to moderate papular-pustular acne of the facial area. For the topical treatment of papulopustular rosacea.
Bayer HealthCare announced that the FDA has approved Finacea (azelaic acid) Foam, 15% for the topical treatment of the inflammatory...
The FDA) has approved Bio-T-Gel, which is licensed by BioSante to Teva Pharmaceuticals USA, Inc. Bio-T-Gel is a testosterone gel...
Allergan plc announced that the Company has received approval from the FDA to market Aczone (dapsone) Gel, 7.5%, a new...
Valeant Pharmaceuticals International, Inc. has announced that it has received approval from the FDA for Onexton Gel (clindamycin phosphate and...
Sol-Gel Technologies, Ltd. announced an update regarding the FDA approval process for Epsolay (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults. In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for Epsolay is April 26, 2021.
Endo International plc has announced that it has introduced the first and only generic 2% topical testosterone gel, an authorized...
The injectable ACTH gel medication Cortrophin Gel (repository corticotropin injection), first introduced in the U.S. in the 1950s, will now be relaunched by ANI Pharmaceuticals as a treatment for acute flare-ups in multiple sclerosis (MS) and other autoimmune conditions, following its approval by the FDA.
Objectives: EASE was a double-blind, randomized, vehicle-controlled, phase III study to determine the efficacy and safety of the topical gel Oleogel-S10 (birch triterpenes) in EB. EASE was funded by Amryt Research Limited.